OncoMatch/Clinical Trials/NCT03216525
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Is NCT03216525 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Alvimopan for bladder cancer.
Treatment: Alvimopan — To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in quicker return of bowel function (GI-2 recovery = time to upper \[first toleration of solid food\] and lower \[first bowel movement\] gastrointestinal recovery) compared to placebo.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Performance status
ASA 1–4
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: prior neoadjuvant chemotherapy allowed if >1 month before surgery
Chemotherapy for bladder cancer within 1 month of scheduled surgery; prior neoadjuvant chemotherapy allowed
Lab requirements
Kidney function
no end-stage renal disease
Liver function
no severe hepatic impairment
Cardiac function
no heart failure
Patients with severe hepatic impairment [excluded]. Patients with end-stage renal disease [excluded]. Patients with heart failure [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03216525 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages